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Abstract
Introduction: Improved methods to optimize drug dosing in the critically ill are urgently needed. Traditional
prescribing culture involves recognition of factors that mandate dose reduction (such as renal impairment),
although optimizing drug exposure, through more frequent or augmented dosing, represents an evolving strategy.
Elevated creatinine clearance (CLCR) has been associated with sub-therapeutic antibacterial concentrations in the
critically ill, a concept termed augmented renal clearance (ARC). We aimed to determine the prevalence of ARC in
a cohort of septic and traumatized critically ill patients, while also examining demographic, physiological and illness
severity characteristics that may help identify this phenomenon.
Methods: This prospective observational study was performed in a 30-bed tertiary level, university affiliated, adult
intensive care unit. Consecutive traumatized and septic critically ill patients, receiving antibacterial therapy, with a
plasma creatinine concentration ≤110 μmol/L, were eligible for enrolment. Pulse contour analysis (Vigileo / Flo
Trac® system, Edwards Lifesciences, Irvine, CA, USA), was used to provide continuous cardiac index (CI) assessment
over a single six-hour dosing interval. Urinary CLCR measures were obtained concurrently.
Results: Seventy-one patients contributed data (sepsis n = 43, multi-trauma n = 28). Overall, 57.7% of the cohort
manifested ARC, although there was a greater prevalence in trauma (85.7% versus 39.5%, P <0.001). In all patients,
a weak correlation was noted between CI and CLCR (r = 0.346, P = 0.003). This was mostly driven by septic patients
(r = 0.508, P = 0.001), as no correlation (r = -0.012, P = 0.951) was identified in trauma. Those manifesting ARC
were younger (P <0.001), male (P = 0.012), with lower acute physiology and chronic health evaluation (APACHE) II
(P= 0.008) and modified sequential organ failure assessment (SOFA) scores (P = 0.013), and higher cardiac indices
(P = 0.013). In multivariate analysis, age ≤50 years, trauma, and a modified SOFA score ≤4, were identified as
significant risk factors. These had greater utility in predicting ARC, compared with CI assessment alone.
Conclusions: Diagnosis, illness severity and age, are likely to significantly influence renal drug elimination in the
critically ill, and must be regularly considered in future study design and daily prescribing practice.
Introduction
Accurate pharmaceutical prescription remains uniquely
challenging in the critically ill. Many dosing schedules are
simply extrapolated from data derived from healthy volun-
teers or ambulatory patients, without consideration of the
pathophysiology [1] or clinical heterogeneity, often
encountered in this setting. Capillary leak, fluid loading,
decreased protein binding, use of vasoactive medications
and altered excretory organ function, will significantly dis-
tort the ‘normal’ pharmacokinetic (PK) profile of many
agents [2]. Most concerning is the potential effects on
antibacterial drug exposure, given the wealth of data
demonstrating improved outcomes with early appropriate
therapy [3-5]. Although infrequently considered, such
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issues may not only confound the successful individual
use of many pharmaceuticals, but also the planning,
methodology and interpretation of clinical trials in this
population [6].
A key PK variable of interest is drug clearance (CL), with
previous data demonstrating notably elevated values in
subsets of critically ill patients [7]. This phenomenon has
recently been termed augmented renal clearance (ARC)
[8] and may significantly impact the successful application
of many renally eliminated agents by promoting sub-thera-
peutic drug exposure [8,9]. Although specific data con-
cerning drug CL in critical illness remains sparse, elevated
urinary creatinine clearance (CLCR), as a marker of ARC,
has been documented in sepsis [10], ventilator associated
pneumonia [11], traumatic brain injury [12], burns [13],
multi-trauma [14] and post-operatively [15]. Furthermore,
elevated CLCR has been closely linked with sub-therapeutic
b-lactam antibacterial trough concentrations [16,17] in
addition to being significantly correlated with renal drug
elimination [7].
Identification of patients manifesting ARC remains
clinically challenging, principally as many agents (most
notably antibacterials) manifest ‘silent’ pharmacodynamic
indices, making under-dosing substantially less visible
[18]. Although various mathematical estimates of glomer-
ular filtration are widely applied [19,20], each was primar-
ily designed for use outside of the ICU, making
application in this setting flawed [21,22] and of little
value in guiding therapy. While a measured CLCR has
greater utility [23], a defined urinary collection period is
required, thereby limiting application to initial dose selec-
tion. Improved methods to identify patients with ARC
using simple bedside assessment are urgently required.
The physiological alterations promoting ARC remain
poorly understood. In large animal models of gram-nega-
tive sepsis, elevated cardiac index (CI), low systemic vas-
cular resistance, and increased major organ blood flow
have been demonstrated [24]. Application of aggressive
fluid resuscitation [25] and vasopressor support [26]
further augments this process, leading to substantial
changes in renal function. Many parallels can be drawn
with pregnancy, where similar cardiovascular changes are
associated with augmented renal blood flow and glomer-
ular filtration [27]. As such, in the absence of established
acute kidney injury (AKI), the innate hemodynamic
response to critical illness, coupled with common clinical
interventions, may promote increased solute delivery to
the kidneys and subsequent augmented renal elimination.
In this respect, assessment of CI offers a logical, prag-
matic and physiologically sound method of rapidly
assessing patients for the presence of ARC. To our
knowledge, there has been little data reported on this
application, representing a new, unique, indication for
cardiovascular monitoring. Importantly, although CI
assessment has historically employed invasive techniques
(such as pulmonary artery catheterization), a variety of
new devices are making continuous CI measurement
accessible, feasible and safe [28]. The aims of this pilot
prospective observational study were, therefore, to: a)
describe the prevalence of ARC in a cohort of septic
and traumatized critically ill patients receiving antibac-
terial therapy; b) correlate CLCR and CI in these
patients; and c) examine demographic, physiological and




Patients were enrolled consecutively as part of a wider
open label study examining b-lactam antibacterial PK in
critical illness, the methodology of which has been pub-
lished elsewhere [29]. In brief, patients were eligible for
enrolment if they were: a) 18 to 80 years of age; and b)
receiving piperacillin-tazobactam for treatment of pre-
sumed or confirmed nosocomial infection, while mani-
festing a systemic inflammatory response syndrome
(SIRS) [30], or were receiving cefazolin as prophylaxis
following multi-trauma. This, therefore, represents a
convenience sample of multi-trauma and septic critically
ill patients admitted to our institution. This manuscript
reports a separate, independent analysis, focusing on
ARC. The study protocol was approved by our institu-
tional human research ethics committee (HREC 2007/
188) and informed consent was obtained from either the
patient or their substitute decision maker in all cases.
Study protocol
An in-depth physiological and PK investigation was per-
formed over a single six-hour dosing interval following
antibacterial infusion [29]. Pulse contour analysis, utiliz-
ing the Vigileo® system (software version 1.10), con-
nected to an existing intra-arterial catheter via a Flo
Trac® (Edwards Lifesciences, Irvine, CA, USA) sensor,
was employed as the primary method of measuring CI.
Demographic data including patient age, gender, body
weight and height were inputted, following which the
sensor was levelled to the phlebostatic axis and ‘zeroed’
to atmospheric pressure. The system provides continu-
ous cardiac output data utilizing the heart rate and an
index of stroke volume (obtained from the arterial pres-
sure waveform), which is automatically averaged and
updated. CI (L/min/m2) is then calculated as the cardiac
output (L/min) divided by the body surface area (BSA)
(m2). Three CI measurements were recorded at 0, 180,
and 300 minutes, after which the mean value was calcu-
lated for use in subsequent analysis.
CLCR was measured as the primary method of deter-
mining kidney function. All urine was collected via an
Udy et al. Critical Care 2013, 17:R35
http://ccforum.com/content/17/1/R35
Page 2 of 9
indwelling catheter over three two-hour time periods (0
to 120, 120 to 240, and 240 to 360 minutes, respec-
tively), following which urinary volume and creatinine
concentration were determined by laboratory analysis.
Creatinine measurement in plasma and urine utilized
automated analyzers employing a modified Jaffe (alkaline
picrate) technique, representing an isotope dilution mass
spectrometry (IDMS) traceable assay. Plasma creatinine
concentrations measured on the day of investigation
were used to calculate each CLCR (normalized to a BSA
of 1.73 m2), after which the mean value was used in
further analysis.
Additional data, including the requirement for mechan-
ical ventilation, vasopressor support, modified sequential
organ failure assessment (SOFA) score (excluding the
neurological component) and 24-hour fluid balance, were
also recorded on the day of drug administration. Admis-
sion acute physiology and chronic health evaluation
(APACHE) II score, in addition to ICU and in-hospital
clinical outcomes, were also recorded. Given that changes
in cardiovascular physiology are unlikely to promote
enhanced renal elimination in the setting of evolving
AKI, patients with a plasma creatinine concentration
greater than the upper limit of the reported reference
range (>110 μ mol/L) were excluded from further analy-
sis. ARC was defined as a CLCR ≥130 ml/min/1.73 m
2,
given previous data demonstrating an association with
sub-therapeutic b-lactam concentrations, when using
standard doses [17].
Statistics
Continuous data are presented as the mean (SD) or
median [IQR]. Categorical data are presented as counts
(%). Correlation was assessed by means of a scatter
graph and Pearson correlation coefficient (r). Compari-
sons between groups utilized an Independent Student
T-test or Mann-Whitney U test for continuous data,
and a Chi-square or Fishers Exact test for categorical
data, where analysis assumptions were met. A backward
conditional logistic regression model was developed to
describe risk factors for ARC in multivariate analysis.
Covariates were identified if the associated P-value was
<0.15 in univariate testing, and the Hosmer-Lemeshow
statistic was used to assess goodness of fit. Receiver
operator characteristic (ROC) curves were constructed
to examine the accuracy of any variable to predict ARC.
A P-value <0.05 was considered as indicating statistical
significance, and all analyses were performed using SPSS
version 19 (Chicago, IL, USA).
Results
Eighty patients were enrolled in the open label PK study,
fifty meeting the criteria for sepsis, and the remaining
thirty admitted post multi-trauma. One patient was
excluded from further analysis as no CI measurements
were available, while a further eight patients were
excluded due to a plasma creatinine concentration >110
μmol/L on the day of study. Laboratory, demographic,
illness severity and outcome data for the remaining
seventy-one patients (sepsis n = 43, multi-trauma n =
28) are presented in Table 1. As expected, young male
patients dominated the multi-trauma group, although
illness severity scores were similar between diagnostic
categories. Data collection occurred a median of 1.60
[1.20 to 2.13] days post admission in the trauma sub-
group, compared with 4.11 [1.68 to 6.83] days in sepsis
Table 1 Laboratory, demographic and illness-severity data of all patients (n = 71).
Variable All patients (number = 71) Trauma (number = 28) Sepsis (number = 43) P-valuea
Age, years, mean (SD) 42.4 (16.6) 36.4 (13.9) 46.3 (17.1) 0.013
Male gender, number (%) 45 (63.4) 23 (82.1) 22 (51.2) 0.008
BSA, m2, mean (SD) 1.98 (0.26) 2.01 (0.25) 1.96 (0.27) 0.415
APACHE II score, mean (SD) 17.9 (7.15) 16.1 (7.68) 19.0 (6.62) 0.096
Modified SOFA score, median [IQR] 3 [2-5] 3.5 [2-5] 3 [2-5] 0.659
Use of Vasopressors, number (%) 20 (28.2) 11 (39.3) 9 (20.9) 0.093
Mechanical ventilation, number (%) 66 (93.0) 26 (92.9) 40 (93.0) 1.000
24hour Fluid balance, ml, mean (SD) 656 (1,886) 1,209 (1903) 295 (1,806) 0.045
Plasma CR, μmol/L, mean (SD) 66.1 (18.1) 62.7 (13.2) 68.4 (20.5) 0.157
CI, L/min/m2, mean (SD) 4.20 (1.10) 4.30 (0.86) 4.13 (1.23) 0.507
CLCR, ml/min/1.73 m
2, mean (SD) 135 (51.8) 166 (42.5) 114 (47.2) <0.001
Augmented renal clearance, n (%) 41 (57.7) 24 (85.7) 17 (39.5) < 0.001
ICU length of stay, days, mean (SD) 16.0 (11.1) 13.3 (10.2) 17.8 (11.4) 0.090
ICU mortality, number (%) 3 (4.20) 1 (3.6) 2 (4.7) 1.000
Hospital mortality, number (%) 6 (8.50) 3 (10.7) 3 (7.0) 0.674
aComparison between sub-groups. APAHCE II, Acute Physiology and Chronic Health Evaluation; BSA, body surface area; CI, cardiac index; CLCR, creatinine
clearance; CR, creatinine concentration; SOFA, Sequential Organ Failure Assessment.
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(P <0.001). Crude ICU (4.2%) and in-hospital (8.5%)
mortality were remarkably low.
Overall, 57.7% of the cohort manifested ARC (CLCR
≥130 ml/min/1.73 m2), although higher CLCR values were
noted in traumatized patients (166 (42.5) versus 114
(47.2) ml/min/1.73 m2, P <0.001), leading to a greater
prevalence in this group (85.7% versus 39.5%, P <0.001).
The range of CI and CLCR measures observed in each
diagnostic sub-group are presented in Figure 1. In all
patients (n = 71), a weak, statistically significant correla-
tion was evident between CI and CLCR (r = 0.346, P =
0.003), although this was primarily due to the relationship
observed in septic patients (r = 0.508, P = 0.001), as no
correlation (r = -0.012, P = 0.951) was evident in trauma
patients (see Figure 2).
Differences in demographic, illness severity, physiologi-
cal and laboratory data on the basis of ARC status are pro-
vided in Table 2. As illustrated, those manifesting ARC
tended to be younger (P <0.001), male (P = 0.012), with
lower APACHE II (P = 0.008) and modified SOFA scores
(P = 0.013) and higher cardiac indices (P = 0.013). The
range of values recorded for age, CI, CLCR and modified
SOFA score are presented graphically in Figure 3.
Linear variables associated with ARC were then dichot-
omized to facilitate multivariate logistic regression. Cut-
points were identified from visual inspection of the data
(Figures 3). Specifically, age ≤50 years, CI ≥3.5 L/min/m2
and modified SOFA score ≤4, along with gender and
diagnostic sub-group, were entered as categorical vari-
ables into a backward conditional regression model.
APACHE II scores were not included, as these are co-lin-
ear with age and SOFA, and poorly validated in trauma.
This analysis identified age ≤50 years (adjusted odds ratio
(OR) 28.6, 95% CI 4.4 to 187.2), trauma (adjusted OR
16.1, 95% CI 3.0 to 87.7) and modified SOFA score ≤4
(adjusted OR 5.1, 95% CI 1.0 to 25.0) as statistically sig-
nificant risk factors for ARC. The r2 value was 0.59, and
the Hosmer-Lemeshow statistic had a significance value
of P = 0.834, suggesting acceptable goodness of fit. There
was no improvement in model performance when contin-
uous variables were utilized.
To further illustrate the relative significance of these
covariates, a weighted scoring system was constructed
based on the adjusted ORs and their proportions to each
other. Age ≤50 years was assigned six points, admission
post-trauma three points and modified SOFA score ≤4
one point. Scores were then summated for each patient,
with higher totals strongly associated (P <0.001) with ARC
(see Figure 4). This model was also compared with CI
measurement as a predictor of ARC status using ROC
analysis (see Figure 5). CI values alone demonstrate an
area under the curve (AUC) of 0.67 (95% CI 0.54 to 0.81,
P = 0.013), whereas the combined ARC score has
improved accuracy, with an AUC of 0.89 (95% CI 0.80 to
0.97, P <0.001). Separate ROC curves were also con-
structed utilizing CI values in each diagnostic sub-group
(figures not displayed). In those manifesting trauma, CI
was less discriminating, with an AUC of 0.57 (95% CI 0.31
to 084, P = 0.646), although this variable performed better
in sepsis, AUC 0.72 (95% CI 0.57 to 0.87, P = 0.015).
Discussion
This pilot investigation, in the context of a larger study
examining b-lactam antibacterial PK in the critically ill
[29], has explored the relationship between CI and CLCR
in a cohort of septic and traumatized patients with
Figure 1 Box plot of CI (L/min/m2) and CLCR (ml/min/1.73 m
2)
in trauma and septic patients. Box plot (median, interquartile
range, maximum and minimum) of cardiac index, L/min/m2 (A) and
creatinine clearance, ml/min/1.73 m2 (B) in trauma (n = 28) and
septic (n = 43) patients. Higher CLCR values were demonstrated in
those admitted post trauma (P <0.001).
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normal plasma creatinine concentrations. Overall, ARC
was present in more than 50%, similar to a previous
report in critically ill patients receiving anti-infective
therapy [31]. A greater prevalence of ARC was noted in
those suffering multi-trauma (85.7%). In univariate ana-
lysis, a statistically significant association between higher
CI and ARC (P = 0.013) was observed, while in multi-
variate modelling, age (≤50 years), diagnostic category
(trauma) and modified SOFA score (≤4) were identified
as significant risk factors for ARC.
These findings principally suggest that the underlying
disease process and physiological reserve, more than any
specific cardiovascular parameter, are implicated in the
development of ARC. This is highly clinically relevant,
given the potential for significant sub-therapeutic drug
exposure when employing ‘standard’ doses in such
patients. Relevant examples include increased clinical
failure [32] or drug resistance [33] with b-lactam anti-
bacterial therapy or sub-optimal venous thromboembo-
lism prophylaxis in those receiving low molecular
weight heparin [34].
Multi-trauma has already been identified as a significant
risk factor for ARC [9,12,14] and this is further confirmed
by our findings. The absence of any correlation between
CI and CLCR in trauma is likely related to the higher CLCR
measures observed in this group, the narrow range of
recorded cardiac indices (see Figure 1) and the smaller
sample size. Furthermore, recruitment of renal reserve
[35], typically seen in states characterized by protein load-
ing [36], may potentially augment glomerular filtration in
this setting, independent of changes in CI.
Importantly, the high prevalence of ARC observed in
the trauma sub-group, despite the limited value of CI
measurement as a discretionary variable, has consider-
able potential ramifications for both future study design
[6] and daily prescribing practice. Specifically, this find-
ing reminds the clinician that a ‘one size fits all’
approach to drug dosing in critical illness, is flawed and
requires adjustment for a number of variables, least of
which is diagnostic category. The recent poor results
from clinical trials of emerging antibacterial agents in
ventilator associated pneumonia [6] further illustrate
this concept. Selecting a single dosing regimen for all
study participants is unlikely to accommodate the range
of clinical and physiological characteristics encountered.
The lower prevalence of ARC (39.5%) and greater
variability in CLCR and CI in the septic sub-group (Fig-
ure 1) reflects the heterogeneity of this syndrome and
the wider spectrum of age and underlying co-morbid
disease. Such variables significantly impact the available
physiological reserve and, as such, the likelihood of
manifesting augmented clearances. This is evidenced by
Figure 2 Correlation of CI (L/min/m2) and CLCR (ml/min/1.73
m2). Scatter graphs of cardiac index (L/min/m2) and creatinine
clearance (ml/min/1.73 m2) in all patients (A), septic patients (B) and
trauma patients (C). The Pearson correlation coefficient (r) for all
patients was r = 0.346 (P = 0.003), septic patients r = 0.508 (P =
0.001), and trauma patients r = -0.012 (P = 0.951).
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the strong overall association between ARC, lower mod-
ified SOFA scores and age, findings which are consistent
with previous literature [37]. Identification of additional
drivers of ARC in septic patients is not possible with the
current dataset, although this is likely to reflect the
interaction between the innate inflammatory response
and available organ reserve.
Previous data examining the relationship between CI
and renal solute elimination in critical illness are limited.
Specifically, Brown et al. sequentially assessed CLCR in
fifty relatively young critically ill post-operative trauma
and non-trauma patients while simultaneously measuring
CI via a pulmonary artery catheter (PAC) [15]. After
exclusion of those receiving inotropes or diuretics and
those with sepsis or renal failure, a modest correlation was
established between CI and CLCR (r = 0.63, P <0.01) [15].
Our study extends these findings, with data distinct from a
peri-operative setting and suggests a modest correlation
Table 2 Demographic, diagnostic and treatment-related data in those with and without augmented renal clearance.
Variable ARC (number = 41) No ARC (number = 30) P-value
Age, years, mean (SD) 34.1 (11.7) 53.7 (15.5) <0.001
Male gender, number (%) 31 (75.6) 14 (46.7) 0.012
BSA, m2, mean (SD) 1.98 (0.25) 1.99 (0.28) 0.850
APACHE II score, mean (SD) 16.0 (6.33) 20.4 (7.49) 0.008
Modified SOFA score, median [IQR] 3 [2-4] 4 [3-6] 0.013
Use of vasopressors, number (%) 9 (22.0) 11 (36.7) 0.173
Mechanical ventilation, number (%) 39 (95.1) 27 (90.0) 0.644
24 hr Fluid balance, ml, mean (SD) 428 (2011) 967 (1684) 0.237
CI, L/min/m2, mean (SD) 4.47 (1.01) 3.80 (1.12) 0.013
CLCR, ml/min/1.73 m










APACHE II, Acute Physiology and Chronic Health Evaluation score; BSA, body surface area; CI, cardiac index; CLCR, creatinine clearance; SOFA, Sequential Organ
Failure Assessment.
Figure 3 Box plot of age (years), CI (L/min/m2), CLCR (ml/min/
1.73 m2) and modified SOFA score in patients with and
without augmented renal clearance. Box plot (median,
interquartile range, maximum and minimum) of age, years (A),
cardiac index, L/min/m2 (B), creatinine clearance, ml/min/1.73 m2
(C) and modified SOFA score (D), in those with (n = 41) and
without (n = 30) augmented renal clearance. Younger age (P
<0.001), higher cardiac indices (P = 0.013) and lower modified SOFA
scores (P= 0.013) were observed in those manifesting augmented
renal clearance.
Figure 4 Proportion of patients manifesting augmented renal
clearance with increasing ARC risk scores. Summated risk scores
were grouped into three categories (0 to 3, 4 to 6, 7 to 10) and the
proportion of patients manifesting augmented renal clearance
determined in each. Higher scores were strongly associated with a
greater prevalence of augmented renal clearance (P <0.001).
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between CI and CLCR in critically ill septic patients (r =
0.508, P = 0.001).
The influence of common critical care interventions on
cardiovascular and renal function remains to be accu-
rately determined. Specifically, although improvements in
CLCR following intravenous fluid administration [25,38]
and use of vasopressor agents [26,39] have been noted in
large animal models, we did not observe any statistically
significant difference in either the requirement for vaso-
pressors (P = 0.173) or 24-hour fluid balance (P = 0.237)
in those manifesting ARC. Importantly, these data could
be misleading, as they represent information obtained
around the time of drug dosing only and, therefore, fail
to consider any prior interventions.
Minimally invasive pulse contour cardiac output analysis
was employed in this study primarily due to ease of appli-
cation and decreasing use of PACs in routine clinical prac-
tice [40]. Although mixed results have been reported in
prior validation studies [41], particularly with the earlier
software [42], later iterations have improved the accuracy
of the device [43], with an acceptable percentage error
[41] and concordance rate [44] in comparison to PAC
thermodilution. Aortic valve abnormalities are still likely
to cause discrepancy [45] through distortion of the pulse
contour, although they were not actively screened for in
our analysis. Importantly, despite the growing use of pulse
contour cardiac output analysis in clinical practice, its use
in general intensive care remains controversial [46] and
must be recognized as a limiting factor in this analysis.
Despite the perceived inaccuracies of any specific
device(s), our findings indicate a potential new, unique,
direction for minimally invasive CI monitoring in criti-
cally ill septic patients. The modest correlation observed
between CI and CLCR, in addition to the ROC analysis,
suggests that elevated values may be viewed as a clinical
‘trigger’ in patients without AKI, to re-consider the dos-
ing strategy in use, particularly in relation to antibacterial
therapy. While additional prospective studies utilizing
drug PK data are urgently required, clinical trials examin-
ing the efficacy of new agents in this setting must be cog-
nisant of these findings [6]. Importantly, our data is
limited temporally, such that we do not report changes in
CI and CLCR during the ICU stay. As critical illness
represents a highly dynamic state, ongoing CI measure-
ment may be even more useful in tailoring drug prescrip-
tion over time.
We have not included specific drug PK data in these
analyses for the following reasons: a) routine measure-
ment of drug levels (b-lactam or otherwise) is infre-
quent; b) CI and CLCR assessment are much more
accessible in clinical practice; and c) CLCR (allowing
identification of ARC) was the primary end-point of
interest. In addition, ARC may influence drug handling
for many different pharmaceuticals, as CLCR is recog-
nized as a key PK covariate for renally eliminated agents
[8,16,17]. It is acknowledged that CLCR is not a ‘gold
standard’ measure of glomerular filtration (such as inu-
lin clearance), albeit tubular creatinine secretion is unli-
kely to influence the result at higher filtration rates [47].
Two-hour urinary collections were employed, as prior
research has reported acceptable accuracy compared
with longer time-periods [48]. The implications of the
proposed ARC scoring system are also acknowledged,
with the current findings being primarily speculative.
Separate, large, multicenter validation studies are
required, in order to establish its external validity, and
assess any potential clinical utility.
Conclusions
To our knowledge, this is the first study to correlate CI
and CLCR in a range of critically ill patients, in addition
to investigating the application of pulse contour cardiac
output monitoring as a means of identifying augmented
renal solute elimination. Our findings suggest that diag-
nostic category, illness severity, age and organ function
are likely to significantly influence the probability of
developing ARC and should be more regularly considered
in future study design and daily prescribing practice. Spe-
cifically, these factors may be useful in identifying
patients at risk of altered drug handling in critical illness.
While additional PK data are required, these results
Figure 5 Receiver Operating Characteristic (ROC) curve of CI (L/
min/m2) and ARC risk score in predicting augmented renal
clearance. ROC curve of cardiac index, L/min/m2 (dashed line) and
ARC risk score (solid line). Cardiac index demonstrates an AUC of
0.67 (95% CI 0.54 to 0.81, P = 0.013), whereas the ARC risk score has
improved accuracy, with an AUC of 0.89 (95% CI 0.80 to 0.97, P
<0.001). A diagonal reference line (AUC = 0.5) is also provided.
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provide a robust basis on which to undertake larger clini-
cal investigation, specifically focusing on the development
of improved drug dosing algorithms in the critically ill.
Key messages
•Augmented renal clearance appears to be common in
critically ill patients with normal plasma creatinine con-
centrations who are receiving antibacterial therapy in
the ICU.
• Young trauma patients, without significant organ
dysfunction, appear to be at greater risk.
• The correlation between cardiac index and urinary
creatinine clearance is better in critically ill septic
patients than in trauma patients.
• Minimally invasive pulse counter cardiac output
monitoring may have a role in identifying critically ill
septic patients with augmented renal clearance.
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